Xvivo Perfusion Forecast, price target & analysts
Xvivo Perfusion Target price 2025 - Analyst rating & recommendation
Xvivo Perfusion Classifications & Recommendation:
Xvivo Perfusion Price Target
| Target Price | kr392.70 |
| Price | kr171.60 |
| Potential |
128.85%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Xvivo Perfusion 2026 .
The average Xvivo Perfusion target price is kr392.70.
This is
128.85%
register free of charge
kr546.00
218.18%
register free of charge
kr202.00
17.72%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend Xvivo Perfusion to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Xvivo Perfusion stock has an average upside potential 2026 of
128.85%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million kr | 822.42 | 823.97 |
| 37.63% | 0.19% | |
| EBITDA Margin | 18.83% | 22.81% |
| 74.25% | 21.12% | |
| Net Margin | 20.94% | 9.06% |
| 36.24% | 56.72% |
8 Analysts have issued a sales forecast Xvivo Perfusion 2025 . The average Xvivo Perfusion sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Xvivo Perfusion EBITDA forecast 2025. The average Xvivo Perfusion EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Xvivo Perfusion Analysts have issued a net profit forecast 2025. The average Xvivo Perfusion net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share kr | 5.44 | 2.37 |
| 77.20% | 56.43% | |
| P/E | 72.44 | |
| EV/Sales | 6.87 |
7 Analysts have issued a Xvivo Perfusion forecast for earnings per share. The average Xvivo Perfusion EPS is
This results in the following potential growth metrics and future valuations:
Xvivo Perfusion...
Current Xvivo Perfusion Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| STIFEL, FORMERLY BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Jul 29 2025 |
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Jul 28 2025 |
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Jul 14 2025 |
| STIFEL, FORMERLY BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Jul 14 2025 |
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Jul 13 2025 |
| STIFEL, FORMERLY BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Jul 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
STIFEL, FORMERLY BRYAN GARNIER:
Locked
➜
Locked
|
Jul 29 2025 |
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Jul 28 2025 |
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Jul 14 2025 |
|
Locked
STIFEL, FORMERLY BRYAN GARNIER:
Locked
➜
Locked
|
Jul 14 2025 |
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Jul 13 2025 |
|
Locked
STIFEL, FORMERLY BRYAN GARNIER:
Locked
➜
Locked
|
Jul 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
